

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2025 (09.01.2025)



(10) International Publication Number
WO 2025/008574 A1

(51) International Patent Classification:

C07D 211/54 (2006.01) C07D 413/12 (2006.01)
C07D 401/06 (2006.01) A61K 31/445 (2006.01)
C07D 401/12 (2006.01) A61K 31/453 (2006.01)
C07D 401/14 (2006.01) A61K 31/454 (2006.01)
C07D 405/12 (2006.01) A61K 31/4545 (2006.01)
C07D 405/14 (2006.01) A61P 25/04 (2006.01)

(21) International Application Number:

PCT/FI2024/050372

(22) International Filing Date:

04 July 2024 (04.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20237131 05 July 2023 (05.07.2023) FI

(71) Applicant: **ORION CORPORATION** [FI/FI]; Orionintie 1, FI-02200 Espoo (FI).

(72) Inventors: **AHLMARK, Marko**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **HAIKARAINEN, Anssi**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **KOIVISTO, Ari-Pekka**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **KUMPULAINEN, Esa**; c/o ORION CORPORATION, P.O. Box 65, FI-02101 Espoo (FI). **SAHARI, Aleksis**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **TURKU, Ainoleena**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **VÄISÄNEN, Emilia**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI).

(74) Agent: **ORION CORPORATION**; P.O.Box 65, FI-02200 Espoo (FI).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,


HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: 2-PHENOXY-1-(4-(ALKYLSULFONYL)PIPERIDIN-1-YL)ETHAN-1-ONE AND 3-PHENYL-1-(4-(ALKYLSULFONYL)PIPERIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AS GPR183 ANTAGONISTS FOR THE TREATMENT OF CHRONIC PAIN



(57) Abstract: The disclosure relates to compounds of formula I, wherein X, and R₁-R₄, n, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I exhibit GPR 183 antagonistic activity and are thus useful in the treatment or prevention of disorder, condition, or disease where GRP183 antagonist is indicated to be useful, such as e.g. chronic pain e.g. osteoarthritis, chronic low back pain, neuropathic pain and immune system diseases e.g. inflammatory bowel diseases e.g. Colitis and Chron's diseases, multiple sclerosis, rheumatoid arthritis, inflammatory pulmonary diseases e.g. asthma and psoriasis.

WO 2025/008574 A1